Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer.
Neoadjuvant chemotherapy is indicated in patients who can tolerate the side effects of a chemotherapy and with preoperative presentation of one of the following clinical risk situations: bulky disease with a maximal tumor diameter of > 4 cm, suspicious lymph nodes in magnetic resonance imaging (MRI), computed tomography (CT) scan or endosonography, histopathologically confirmed lymph node metastasis, or histopathologically documented risk factors such as G3 and L1V1. A neoadjuvant chemotherapy followed by surgery should be performed with cisplatin at a dosage of > 25 mg/m2 per week and an application interval of < 14 days. The previously published data suggests an improved rate of complete resection and reduced incidences of positive lymph nodes and parametric infiltration. Accordingly, the percentage of patients in need for adjuvant radiochemotherapy after operation can be significantly reduced. Some studies demonstrated a prolongation of progression-free and overall survival. Following the previously published studies, adjuvant chemotherapy after operation or after radiochemotherapy has no significant effect on the overall survival and, following the current guidelines, should be avoided.
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Köln, Universitätsklinikum Köln (AöR), Cologne, Germany.
Peter
P
Mallmann
Christoph
C
Mallmann
D059186:Chemoradiotherapy, Adjuvant / Q000379:methods*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D055088:Early Detection of Cancer / Q000379:methods; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D020360:Neoadjuvant Therapy / Q000379:methods; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000628:therapy*